Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions Meeting Abstract

  

Authors:	Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Pratz, K. W.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; Dohner, H.; Pollyea, D. A.; McCloskey, J. K.; Odenike, O.; Lowenberg, B.; Ossenkoppele, G. J.; Patel, P. A.; Roshal, M.; Lersch, F.; Nabhan, S.; Choe, S.; Wang, H.; Hua, L.; Almon, C.; Cooper, M.; Tallman, M. S.
Abstract Title:	Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions
Meeting Title:	60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	132
Issue:	Suppl. 1
Meeting Dates:	2018 Dec 1-4
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2018-11-29
Language:	English
ACCESSION:	WOS:000454837601269
PROVIDER:	wos
DOI:	10.1182/blood-2018-99-110449
Notes:	Meeting Abstract: 560 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/145272